Cagrilintide + Semaglutide
Co-formulated amylin analogue and GLP-1 agonist in a single vial — the CagriSema research model.
16 products
Co-formulated amylin analogue and GLP-1 agonist in a single vial — the CagriSema research model.
Triple GIP / GLP-1 / glucagon receptor agonist — the next generation of incretin research.
Long-acting GLP-1 receptor agonist — the reference compound for incretin-based metabolic research.
Dual GIP and GLP-1 receptor agonist with the deepest weight-change effect of any approved incretin.
Small-molecule NNMT inhibitor studied in adipocyte and diet-induced obesity models.
Once-weekly amylin analogue studied alone and in combination with semaglutide (CagriSema).
Selective, long-acting amylin receptor agonist with 48-week phase 2 data.
The lipolytic C-terminal fragment of human growth hormone.
Lipolytic ampoule solution. Formulation sheet available on request.
Triple-agonist and amylin analogue co-formulated 1:1.
High-mass co-formulation of retatrutide and tirzepatide for combination-agonist studies.
Glucagon / GLP-1 dual agonist in phase 3 for obesity and MASH.
We can often source additional sequences at wholesale volume. Ask us.